INT62041

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.58
First Reported 1996
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 37
Total Number 37
Disease Relevance 37.86
Pain Relevance 5.27

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
dendritic cells 15
basophils 5
mast cells 5
blood 4
lung 4
IGHE (Homo sapiens)
Pain Link Frequency Relevance Heat
Inflammation 540 100.00 Very High Very High Very High
cytokine 454 100.00 Very High Very High Very High
agonist 184 99.98 Very High Very High Very High
substance P 3 99.98 Very High Very High Very High
corticosteroid 199 99.46 Very High Very High Very High
Neuropeptide 5 94.88 High High
Enkephalin 2 93.68 High High
intrathecal 1 93.48 High High
Opioid 1 92.24 High High
Antihistamine 11 85.16 High High
Disease Link Frequency Relevance Heat
Eosinophilia 135 100.00 Very High Very High Very High
Pneumonia 34 100.00 Very High Very High Very High
Disease 422 99.82 Very High Very High Very High
INFLAMMATION 557 99.76 Very High Very High Very High
Asthma 1849 99.52 Very High Very High Very High
Airway Remodeling 32 99.44 Very High Very High Very High
Anaphylaxis 89 99.40 Very High Very High Very High
Chronic Sinusitis 158 99.28 Very High Very High Very High
Cancer 40 98.84 Very High Very High Very High
Multiple Myeloma 7 98.80 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
IgE production is not impaired by the pathologic process in MM patients.
Negative_regulation (impaired) of Gene_expression (production) of IgE associated with multiple myeloma
1) Confidence 0.58 Published 2004 Journal Rinsho Ketsueki Section Abstract Doc Link 15199753 Disease Relevance 0.69 Pain Relevance 0.17
In contrast to ACTH, substance P interfered not only with IgE synthesis but also with the synthesis of the other immunoglobulin isotypes.
Negative_regulation (interfered) of Gene_expression (synthesis) of IgE associated with substance p
2) Confidence 0.55 Published 1996 Journal Exp. Dermatol. Section Abstract Doc Link 8624610 Disease Relevance 0 Pain Relevance 0.58
Comparison of intravenous administration of omalizumab with placebo in patients with mild asthma not receiving inhaled corticosteroids resulted in a significant decrease in serum free IgE levels from baseline concentrations (P<0.00001 and P<0.001 in two separate studies) (Boulet et al. 1997; Fahy et al. 1997).
Negative_regulation (decrease) of Gene_expression (levels) of IgE associated with asthma and corticosteroid
3) Confidence 0.43 Published 2008 Journal Core Evidence Section Body Doc Link PMC2899803 Disease Relevance 0.10 Pain Relevance 0.05
(inhibit IgE production and also inhibit Th2 cytokine generation), TGF ?
Negative_regulation (inhibit) of Gene_expression (production) of IgE associated with cytokine
4) Confidence 0.38 Published 2010 Journal Clin Mol Allergy Section Body Doc Link PMC2837605 Disease Relevance 0 Pain Relevance 0.34
They also showed a decrease in serum levels of sIL-2R, IL-4, IL-5, IgE and eosinophil count.
Negative_regulation (decrease) of Gene_expression (levels) of IgE in eosinophil
5) Confidence 0.38 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2846923 Disease Relevance 0.48 Pain Relevance 0.11
IgE hypogammaglobulinemia is currently defined as a significant decrease in serum levels of IgE (<2.5 IU/mL) in a patient whose other immunoglobulin levels are normal (selective IgE deficiency) or diminished (mixed IgE deficiency).
Negative_regulation (diminished) of Gene_expression (deficiency) of IgE associated with agammaglobulinemia
6) Confidence 0.38 Published 2010 Journal Clin Mol Allergy Section Body Doc Link PMC2837605 Disease Relevance 0.55 Pain Relevance 0
IgE hypogammaglobulinemia is currently defined as a significant decrease in serum levels of IgE (<2.5 IU/mL) in a patient whose other immunoglobulin levels are normal (selective IgE deficiency) or diminished (mixed IgE deficiency).
Negative_regulation (diminished) of Gene_expression (deficiency) of IgE associated with agammaglobulinemia
7) Confidence 0.38 Published 2010 Journal Clin Mol Allergy Section Body Doc Link PMC2837605 Disease Relevance 0.55 Pain Relevance 0
Doses ranging from 0.0005 to 0.14 mg/kg subcutaneously or 0.05 to 1.0 mg/kg intravenously decrease free serum IgE levels in plasma in a dose-dependent fashion in both adults and children (Barnes 2000; Fahy 2000).
Negative_regulation (decrease) of Gene_expression (levels) of IgE in plasma
8) Confidence 0.38 Published 2008 Journal Core Evidence Section Body Doc Link PMC2899803 Disease Relevance 0.31 Pain Relevance 0.04
High levels of IL-4, IL-5 and IL-13 mRNAs, peripheral blood eosinophil count and serum IgE level decreased after surgery and radiation and continued to decrease during cyclosporine therapy.
Negative_regulation (decreased) of Gene_expression (levels) of IgE in blood
9) Confidence 0.37 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2846923 Disease Relevance 0.79 Pain Relevance 0.15
High levels of IL-4, IL-5 and IL-13 mRNAs, peripheral blood eosinophil count and serum IgE level decreased after surgery and radiation and continued to decrease during cyclosporine therapy.
Negative_regulation (decrease) of Gene_expression (levels) of IgE in blood
10) Confidence 0.37 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2846923 Disease Relevance 0.81 Pain Relevance 0.15
A number of studies have demonstrated the beneficial effects of reducing the serum levels of IgE, first by the model of allergen challenge (Boulet et al 1997; Fahy et al 1997) and then by clinical trials in adults and children (Milgrom et al 1999; Solèr et al 2001; Busse et al 2001; Buhl et al 2002; Finn et al 2003; Corren et al 2003; Bousquet et al 2005; Holgate et al 2005; Humbert et al 2005) with severe asthma.
Negative_regulation (reducing) of Gene_expression (levels) of IgE associated with asthma
11) Confidence 0.32 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727776 Disease Relevance 0.63 Pain Relevance 0.21
The results showed a better outcome in patients with free IgE levels decreased to less than 25 IU/mL, who comprised 70% of those actively treated, and significant differences in favor of omalizumab for eye (but not nose) symptoms, use of rescue medication, patient’s evaluation of efficacy, and quality of life.
Negative_regulation (decreased) of Gene_expression (levels) of IgE in eye
12) Confidence 0.32 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727776 Disease Relevance 0.52 Pain Relevance 0.04
Omalizumab decreases free serum IgE levels in a dose-dependent manner, reduces IgE receptor density on effector cells, and significantly improves airway inflammation parameters.
Negative_regulation (decreases) of Gene_expression (levels) of IgE associated with inflammation
13) Confidence 0.29 Published 2004 Journal Treat Respir Med Section Abstract Doc Link 15219177 Disease Relevance 0.45 Pain Relevance 0.13
Omalizumab decreases free serum IgE levels in a dose-dependent manner, reduces IgE receptor density on effector cells, and significantly improves airway inflammation parameters.
Negative_regulation (decreases) of Gene_expression (levels) of IgE associated with inflammation
14) Confidence 0.29 Published 2004 Journal BioDrugs Section Abstract Doc Link 15571425 Disease Relevance 0.45 Pain Relevance 0.13
Omalizumab decreases free IgE levels rapidly and the expression of the high affinity IgE receptor expression on key effector cells, including mast cells, basophils, dendritic cells and monocytes.
Negative_regulation (decreases) of Gene_expression (expression) of IgE in dendritic cells
15) Confidence 0.28 Published 2010 Journal Allergy, Asthma & Immunology Research Section Body Doc Link PMC2946700 Disease Relevance 2.04 Pain Relevance 0.17
Omalizumab decreases free IgE levels rapidly and the expression of the high affinity IgE receptor expression on key effector cells, including mast cells, basophils, dendritic cells and monocytes.
Negative_regulation (decreases) of Gene_expression (expression) of IgE in dendritic cells
16) Confidence 0.28 Published 2010 Journal Allergy, Asthma & Immunology Research Section Body Doc Link PMC2946700 Disease Relevance 1.98 Pain Relevance 0.17
Omalizumab decreases free IgE levels rapidly and the expression of the high affinity IgE receptor expression on key effector cells, including mast cells, basophils, dendritic cells and monocytes.
Negative_regulation (decreases) of Gene_expression (levels) of IgE in dendritic cells
17) Confidence 0.27 Published 2010 Journal Allergy, Asthma & Immunology Research Section Body Doc Link PMC2946700 Disease Relevance 1.87 Pain Relevance 0.17
We speculate that these represented persons who had lost the ability to synthesize substantial amounts of circulating IgE, but still had allergen-specific IgE bound to their cutaneous mast cells.
Negative_regulation (lost) of Gene_expression (synthesize) of IgE in mast cells
18) Confidence 0.11 Published 2005 Journal Respir Res Section Body Doc Link PMC1343550 Disease Relevance 0.84 Pain Relevance 0
Omalizumab decreases free IgE levels rapidly and the expression of the high affinity IgE receptor expression on key effector cells, including mast cells, basophils, dendritic cells and monocytes.
Negative_regulation (decreases) of in basophils Gene_expression (expression) of IgE in dendritic cells
19) Confidence 0.09 Published 2010 Journal Allergy, Asthma & Immunology Research Section Body Doc Link PMC2946700 Disease Relevance 1.98 Pain Relevance 0.17
Omalizumab decreases free IgE levels rapidly and the expression of the high affinity IgE receptor expression on key effector cells, including mast cells, basophils, dendritic cells and monocytes.
Negative_regulation (decreases) of in mast cells Gene_expression (expression) of IgE in dendritic cells
20) Confidence 0.09 Published 2010 Journal Allergy, Asthma & Immunology Research Section Body Doc Link PMC2946700 Disease Relevance 1.98 Pain Relevance 0.17

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox